A clinical trial found that low-dose endoxifen reduced breast density by 19.3% compared to placebo while causing side effects similar to a sugar pill, potentially offering women at elevated breast cancer risk a more tolerable prevention option than existing medications.

What Is Endoxifen and Why Does It Matter for Breast Cancer Prevention?

Endoxifen is the active metabolite of tamoxifen, the most therapeutically potent form of a drug that has been used for decades to prevent breast cancer in high-risk women. Rather than taking tamoxifen and relying on the body to convert it into endoxifen, researchers are testing whether giving endoxifen directly could preserve cancer-fighting benefits while reducing unwanted side effects.

The key innovation here is addressing a major limitation of tamoxifen: its variable metabolism. Different women's bodies break down tamoxifen at different rates, making it unpredictable how much active endoxifen they actually produce. By administering endoxifen directly, researchers hope to create a more consistent and potentially more tolerable approach to breast cancer prevention.

What Did the KARISMA Trial Actually Find?

The KARISMA Endoxifen trial was a randomized, double-blind, placebo-controlled Phase 2 study conducted in Sweden that enrolled 240 healthy premenopausal women aged 40 to 55 years who were participating in the national mammography screening program in Stockholm. Participants received either placebo, 1 milligram of endoxifen daily, or 2 milligrams of endoxifen daily for six months.

The results, published in the Journal of the National Cancer Institute, demonstrated that both doses significantly reduced mammographic breast density (MBD), a well-established risk factor for breast cancer. Here's what the numbers showed:

• 1 mg dose: Reduced breast density by 19.3% compared to placebo, with statistical certainty over 99%
• 2 mg dose: Reduced breast density by 26.5% compared to placebo, with statistical certainty exceeding 99.9%
• Comparison to existing therapy: These reductions were comparable to those previously reported with the standard 20 milligram dose of tamoxifen

What makes these findings particularly significant is that the 1 milligram dose achieved meaningful density reduction while maintaining a tolerability profile essentially identical to placebo. This suggests that women might be able to take this medication long-term without experiencing the bothersome side effects that have limited tamoxifen use in prevention settings.

How Does the Side Effect Profile Compare to Current Options?

One of the biggest barriers to breast cancer prevention with tamoxifen is that women often experience vasomotor symptoms, which include hot flashes and night sweats. The KARISMA trial found that discontinuations due to drug-related adverse events were remarkably similar between the 1 milligram endoxifen group and placebo: 5 participants in the 1 milligram group versus 4 in the placebo group. In contrast, 11 participants receiving the 2 milligram dose discontinued due to side effects.

The trial also found no clinically significant changes in blood tests, blood pressure, heart rate, or physical examination findings. Adverse events that did occur were generally vasomotor in nature, consistent with what researchers have seen with tamoxifen, but they were notably less frequent at the lower dose.

"Prevention requires a paradigm shift from current cancer treatment. A medicine intended for healthy women at elevated risk must be effective, convenient, and acceptable over time. We believe the KARISMA Endoxifen trial gives us a clear signal that low-dose Endoxifen can produce a biologically meaningful reduction in mammographic breast density with a tolerability profile that may support long-term use," said Steven Quay, President and Chief Executive Officer of Atossa Therapeutics.

Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa Therapeutics

Why Is Breast Density Such an Important Risk Factor?

Mammographic breast density refers to the proportion of dense tissue versus fatty tissue visible on a mammogram. Women with higher breast density face a significantly elevated risk of developing breast cancer, and this density is recognized as a pharmacodynamic marker, meaning it's a measurable biological change that indicates a drug is working as intended.

The KARISMA researchers observed that meaningful breast density reduction appeared to occur at relatively low endoxifen plasma concentrations, with the response reaching approximately 20% decrease at concentrations of roughly 3 to 4 nanograms per milliliter. Importantly, no substantial additional density reduction occurred at higher concentrations, suggesting that the 1 milligram dose captures the therapeutic benefit without pushing into the range where side effects become more prominent.

How to Evaluate Whether This Drug Might Be Right for You

• Assess your breast cancer risk: This drug is being developed specifically for women at elevated breast cancer risk, such as those with a family history, genetic mutations like BRCA1 or BRCA2, or high breast density on screening mammograms
• Consider your tolerance for current options: If you've been advised to take tamoxifen for prevention but experienced side effects like hot flashes or night sweats that made adherence difficult, endoxifen's improved tolerability profile may be worth discussing with your doctor
• Understand the development stage: Endoxifen is still in clinical trials and is not yet approved by the FDA for any indication, so it's not yet available as a treatment option outside of research studies
• Discuss future trial participation: If you meet eligibility criteria and are interested in breast cancer prevention research, ask your healthcare provider about upcoming endoxifen trials in your area

What Happens Next in the Research Pipeline?

The KARISMA trial was a proof-of-concept and dose-determining study, meaning it established that endoxifen works and identified the optimal dose. The authors noted that future studies are needed to determine whether endoxifen actually reduces the incidence of breast cancer in women at increased risk.

Atossa Therapeutics, the company developing endoxifen, believes these results strengthen the rationale for advancing the drug as a potential breast density reduction therapy, particularly for women with elevated breast density or other risk factors who may benefit from endocrine risk reduction but are reluctant to use currently available options like tamoxifen.

The key takeaway for women concerned about breast cancer prevention is that researchers are actively working to develop medications that preserve the cancer-fighting benefits of existing drugs while reducing the side effects that make long-term use challenging. The KARISMA trial provides encouraging evidence that this goal may be achievable with endoxifen, though several more years of research will be needed before it becomes available to patients outside of clinical trials.